| By Aesica Pharmaceuticals |
| Monday, 24 September 2007 |
 |
Queenborough acquisition triples workforce, increases capacity and moves Aesica into secondary manufacturing. Aesica took another transformation step towards its vision of becoming the number one supplier of APIs and formulated products to the pharmaceutical industry when it completed the acquisition of the chemical and
|
|
pharmaceutical facilities and operations at Abbott's Queenborough site, on the Isle of Sheppey, Kent, England.
|
|
|
The deal tripled Aesica's workforce, increased capacity and took the company into secondary manufacturing.
The acquisition included the transfer of around 450 staff, bringing the total number of Aesica employees at its three sites to approximately 700 and was accompanied by a supply agreement with Abbott which runs until the end of 2012. Aesica will also actively seek contract manufacturing opportunities to bring the Queenborough facility to full capacity.The Queenborough operations have the capabilities to |
|
formulate and package a wide variety of dosage forms and enable Aesica to extend its service offering to customers by developing manufactured finished products in addition to supplying APIs.
:: View Aesica Corporate Profile ::
:: Aesica Website ::
Want to read more?
Aesica opens office in China
Aesica establishes US subsidiary to drive further growth in North America |
|
|
